By Brazil Stock Guide – Fleury S.A. (B3: FLRY3) acknowledged that negotiations with Rede D’Or São Luiz S.A. (B3: RDOR3) are ongoing, but clarified that no decision has been taken regarding a potential deal. The statement came after O Globo columnist Lauro Jardim reported on a possible suspension of the talks between the two major healthcare groups.
In a regulatory filing released Monday (Oct. 20), the diagnostics company said its management “has not decided to suspend, continue, or not continue” with any transaction involving Rede D’Or, and that “no binding or non-binding documents” have been signed between the parties. The announcement follows months of speculation about consolidation in Brazil’s private healthcare market, where hospital networks and diagnostic firms have been seeking scale and integration to reduce costs and increase bargaining power with insurers.
“Despite ongoing discussions, there is no decision or commitment regarding any operation involving Rede D’Or,” Fleury’s CFO and investor relations head, José Antonio de Almeida Filippo, wrote in the filing.
The statement leaves open the possibility that talks could resume or evolve into a formal proposal. Rede D’Or has been expanding aggressively through acquisitions, while Fleury, which merged with Pardini in 2022, has sought new growth avenues in specialized services and hospital diagnostics.